Blood test may guide heart failure treatment to cut hospital returns

NCT ID NCT02963272

Completed Diagnosis Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

Heart failure is a serious condition with high death and rehospitalization rates. This study tested whether using a blood marker called ST2 to guide treatment could reduce hospital readmissions within one month. Researchers compared standard care with a strategy that adjusts medications based on ST2 levels in 123 hospitalized heart failure patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ST2 biomarker-guided treatment strategy
What this could lead to: If successful, this approach could help doctors personalize heart failure treatment to reduce hospital readmissions and lower healthcare costs.
What could go wrong: This is a small, completed study with 123 participants, so results may not apply to all heart failure patients. The ST2-guided strategy may not significantly reduce readmissions compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIASTOLIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure Fibrosis heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIASTOLIC HEART FAILURE HEART FAILURE SYSTOLIC HEART FAILURE STAGE C

Contacts and locations

Locations

University Regional Hospital Arnaud de Villeneuve

Montpellier, Languedoc-Roussillon, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.